Lung Cancer Therapeutics Market Outlook And Pipeline Analysis
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis
With over 50% of all non-small cell lung cancer (NSCLC) patients diagnosed at the advanced stages of the disease, and 95% of all small-cell lung cancer (SCLC) patients unsuitable for surgical resection, drug therapy plays a vital role in the management of lung cancer. Such high level of unmet need ensures the lung cancer market is an attractive commercial opportunity for new drug development. ( http://www.bharatbook.com/detail.asp?id=132820&rt=Lung-Cancer-Therapeutics-Market-Outlook-and-Pipeline-Analysis.html )
Lung Cancer Therapeutics Market & Pipeline Analysis supports the process of successful product development and commercialization within the pharmaceutical/biopharmaceutical lung cancer market by addressing the following key areas:
* Epidemiology of lung cancer
* Current lung cancer treatments
* Analysis of current lung cancer therapeutics
* Unmet needs within the lung cancer market
* Research and development (R&D) approaches towards lung cancer
* Pipeline analysis of key lung cancer candidates
* Forecast sales of key pipeline lung cancer candidates
The report also analyzes the market status and potential for the following key lung cancer therapies:
* Sanofi-Aventis’ Taxotere (docetaxel)
* Eli-Lilly’s Gemzar (gemcitabine)
* Eli-Lilly’s Alimta (pemetrexed)
* GlaxoSmithKline’s Hycamtin (topotecan) (SCLC therapeutic)
* OSI Pharmaceuticals/Roche’s Tarceva (erlotinib)
* AstraZeneca’s Iressa (gefitinib)
* Roche’s Avastin (bevazicumab)
and the market potential for the following key late-clinical stage developmental candidates:
* Opaxio
* Erbitux (line extensions)
* Zactima
* Picoplatin
This in-depth, quality report delivers:
* An assessment of the lung market potential, including identification of unmet needs, commercial opportunities, and key trends in R&D
* Analysis of the lung cancer pipeline with in-depth clinical and commercial assessment of key Phase III candidates
* Seven major pharmaceutical market sales forecasts to 2015 for key pipeline candidates incorporating product events
Purchasing this report will enable you to:
* Assess opportunities and risks influencing R&D in lung cancer, unmet needs in the treatment of the disease, and trends in current development
* Identify key lung cancer products in late-phase development based on sales forecasts to 2015 to maximize your product’s commercial potential
* Gain an impartial perspective of the strategies used between competing companies involved in the lung cancer pipeline to enhance your product’s performance
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=132820&rt=Lung-Cancer-Therapeutics-Market-Outlook-and-Pipeline-Analysis.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook
–
About the Author:
We are the leading information aggregator, facilitates and supports the business information needs. With over 115,000 reports, you can get instant access and insights on the studies in yo for market research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management, country intelligence, consumer & durable goods, chemical and more ur areas of interest. Contact us at +91 22 27578668 / 27579438 or email info@bharatbook.com or our website www.bharatbook.com
Article Source
